MYC and Burkitt lymphoma: In summary, our results show that in Burkitt lymphoma the MYC oncogene is a client protein of HSP90, and that inhibition of HSP90 function with pharmacologic inhibitors caused a switch in MYC transcription as well as MYC protein destabilization.